# MEDI2228 in Subjects With Relapsed/Refractory Multiple Myeloma

> **NCT03489525** · PHASE1 · COMPLETED · sponsor: **MedImmune LLC** · enrollment: 107 (actual)

## Conditions studied

- Relapsed/Refractory Multiple Myeloma

## Interventions

- **BIOLOGICAL:** Dose Escalation, MEDI2228, ADC (antibody drug conjugate)
- **BIOLOGICAL:** Dose Expansion, MEDI2228, ADC (antibody drug conjugate)

## Key facts

- **NCT ID:** NCT03489525
- **Lead sponsor:** MedImmune LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-05-08
- **Primary completion:** 2022-03-21
- **Final completion:** 2022-03-21
- **Target enrollment:** 107 (ACTUAL)
- **Last updated:** 2022-03-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03489525

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03489525, "MEDI2228 in Subjects With Relapsed/Refractory Multiple Myeloma". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT03489525. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*